Application of a RNF122 inhibitor in the preparation of brain glioma drugs

RNF122 gene silencing using siRNA and delivery with cationic liposomes addresses the limitations of current glioma treatments by inhibiting proliferation and inducing cell cycle arrest, offering a promising molecular targeted therapy.

CN116059373BActive Publication Date: 2024-12-03NANTONG UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202211301580.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-10-24
Publication Date
2024-12-03
Estimated Expiration
2042-10-24

AI Technical Summary

Technical Problem

Current treatments for gliomas, including surgery, radiotherapy, and chemotherapy, are limited by invasive growth, drug resistance, and high recurrence rates, lacking effective specific target genes for molecular targeted therapy.

Method used

Utilizing RNF122 inhibitors, specifically siRNA, shRNA, and sgRNA, to silence the RNF122 gene expression in glioma cells, combined with cationic liposomes for delivery, to inhibit proliferation and induce G2/M cell cycle arrest.

Benefits of technology

Effectively inhibits glioma cell proliferation and induces cell cycle arrest, providing a targeted treatment strategy with potential for improved patient prognosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116059373B_ABST
    Figure CN116059373B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biomedicine technology, and discloses an application of a RNF122 inhibitor in the preparation of a glioma drug. The RNF122 gene is specifically highly expressed in gliomas, and glioma patients with high RNF122 expression have a short overall survival time and a poor prognosis. The present invention finds that siRNA can effectively silence the expression of RNF122 in glioma cells, leading to G2 / M cycle arrest of glioma cells and inhibiting cell proliferation, thereby proving the preventive and therapeutic effect of RNF122 inhibitors on gliomas.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and specifically relates to an application of a RNF122 inhibitor in the preparation of a brain glioma drug. Background Art

[0002] Gliomas are the most common primary brain tumors caused by cancerous changes in glial cells in the brain and spinal cord, accounting for about 50% of brain tumors. Gliomas are highly malignant, with rich blood vessels in the tumor tissue, easy to invade and recur, and have a poor prognosis. Although some achievements have been made in surgical treatment, radiotherapy and chemotherapy, the treatment of gliomas is still limited. Gliomas grow in an invasive manner and have no obvious boundaries with the surrounding normal brain tissue. It is difficult to completely remove them during surgery, and gliomas are prone to resistance to chemotherapy drugs. Therefore, their recurrence rate is still high, and the 5-year survival rate of patients is extremely low. Therefore, there is an urgent need to find new effective treatment strategies for gliomas in clinical practice.

[0003] With the progress of tumor molecular biology research, molecular targeted therapy targeting genes has gradually become a new method for the clinical treatment of malignant tumors, showing unparalleled development potential. Unlike traditional chemotherapy, molecular targeted therapy prevents the growth of cancer cells by interfering with specific target molecules in the occurrence and development of malignant tumors. It has the advantages of strong specificity, obvious efficacy, and few adverse reactions. The occurrence and development of gliomas are closely related to changes in genes or their expression levels. It is a complex process involving multiple genes, and each gene involved may become a target for treatment. However, so far, there are no particularly effective specific target genes for gliomas that can be used in clinical treatment. Therefore, finding effective biological target molecules that can be used in the clinical treatment of gliomas is a key issue to be solved.

[0004] RNF122 is a protein-coding gene that has been reported to be associated with the onset of attention deficit hyperactivity disorder. The possible role of RNF122 in the diagnosis and treatment of brain glioma has not been reported. Summary of the invention

[0005] In order to overcome the deficiencies of the prior art, the technical problem to be solved by the present invention is to provide the use of RNF122 inhibitors in the preparation of glioma drugs. Studies have shown that the expression of RNF122 gene in tumor tissues of glioma patients is significantly higher than that in normal tissues. Moreover, high expression of RNF122 gene is associated with poor prognosis of glioma patients. Inhibiting the expression of RNF122 gene in glioma cells can effectively inhibit cell proliferation and induce G2 / M cell cycle arrest.

[0006] The present invention provides an application of an RNF122 inhibitor in the preparation of a glioma drug. The glioma drug includes one of a drug for inhibiting glioma cell proliferation, a drug for inducing glioma cell cycle arrest and a drug for preventing and treating glioma.

[0007] Based on the inhibitory effect of RNF122 inhibitor on the proliferation of human glioma cells, and the RNF122 inhibitor-induced human glioma cell cycle arrest, the present invention also provides the use of RNF122 inhibitor in the preparation of drugs for preventing and treating human glioma.

[0008] In the present invention, the RNF122 inhibitor refers to a gene silencing technology targeting RNF122, including adenovirus-mediated shRNA interference technology or lentivirus-mediated CrisprCAS9 technology. Further, the RNF122 inhibitor is RNF122siRNA, RNF122shRNA, shRNA encoding DNA or RNF122sgRNA. Among them, RNF122siRNA is a small molecule interfering RNA targeting RNF122, which can cause the degradation of mRNA and silence the RNF122 gene. RNF122shRNA is a short hairpin RNA targeting RNF122, which can be cloned into an expression vector and express short interfering RNA, thereby achieving the silencing of the RNF122 gene. RNF122sgRNA is a guide RNA targeting the RNF122 gene. SgRNA is an important component based on the Crispr gene knockout system, which can bind to the cas9 protein and guide the cas9 enzyme to target genomic DNA to shear the RNF122 gene.

[0009] The drug provided by the present invention also includes cationic liposomes. In the present invention, cationic liposome Lipofectamine 3000 is used as a transfection reagent.

[0010] In some embodiments, the RNF122 inhibitor is an siRNA targeting RNF122, consisting of a complementary sense chain and an antisense chain, wherein the sense chain is a nucleotide sequence as shown in SEQ ID NO.1, and the antisense chain is a nucleotide sequence as shown in SEQ ID NO.2; or, the sense chain is a nucleotide sequence as shown in SEQ ID NO.3, and the antisense chain is a nucleotide sequence as shown in SEQ ID NO.4; or, the sense chain is a nucleotide sequence as shown in SEQ ID NO.5, and the antisense chain is a nucleotide sequence as shown in SEQ ID NO.6.

[0011] Furthermore, the RNF122 inhibitor used is siRNA targeting RNF122, which is composed of complementary sense strands and antisense strands.

[0012] Furthermore, the sense strand of the siRNA of RNF122 is the nucleotide sequence shown in SEQ ID NO.1, and the antisense strand of the siRNA of RNF122 is the nucleotide sequence shown in SEQ ID NO.2.

[0013] Furthermore, the sense strand of the siRNA of RNF122 is the nucleotide sequence shown in SEQ ID NO.3, and the antisense strand of the siRNA of RNF122 is the nucleotide sequence shown in SEQ ID NO.4.

[0014] Furthermore, the sense strand of the siRNA of RNF122 is the nucleotide sequence shown in SEQ ID NO.5, and the antisense strand of the siRNA of RNF122 is the nucleotide sequence shown in SEQ ID NO.6.

[0015] Furthermore, the brain glioma cells are human glioma U251 cells.

[0016] The drug of the present invention further comprises other therapeutic agents, which are selected from other drugs for treating brain glioma. The drug is in the form of injection liquid or powder for injection.

[0017] Advantages and beneficial effects of the present invention:

[0018] The present invention first discovered that the expression of RNF122 gene in tumor tissue of patients with brain glioma is significantly higher than that in normal tissue. Moreover, the high expression of RNF122 gene is related to the poor prognosis of patients with brain glioma. Inhibiting the expression of RNF122 gene in glioma cells can effectively inhibit cell proliferation and induce G2 / M cell cycle arrest. Therefore, RNF122 can be used as an important molecular target for the prevention and treatment of brain glioma, and it is possible to provide a powerful means for the targeted treatment of brain glioma. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 The expression difference of RNF122 gene in normal brain tissue and glioma tissue of glioma patients in TCGA database was shown;

[0020] Figure 2 Show the effect of RNF122 gene expression on the survival rate of patients with brain glioma;

[0021] Figure 3 Effects of different siRNAs on RNF122 gene expression in human glioma cells;

[0022] Figure 4 Show the effect of knocking down the expression of RNF122 gene on the proliferation of glioma cells;

[0023] Figure 5Shows the effect of knocking down the expression of RNF122 gene on the cell cycle of glioma cells. DETAILED DESCRIPTION

[0024] The present invention will be further described in detail below in conjunction with the accompanying drawings and Examples. The following examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the examples where specific conditions are not specified are usually performed under conventional conditions or under conditions recommended by the reagent manufacturer.

[0025] Example 1 Expression differences of RNF122 gene in normal brain tissue and glioma tissue in TCGA database

[0026] TCGA (The cancer genome atlas) is a database jointly developed by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) in 2006. It contains clinical data, genomic variations, mRNA expression, miRNA expression, methylation and other data of various human cancers. It is a very important data source for cancer researchers. RNAseq data of brain glioma were obtained from the TCGA dataset (https: / / portal.gdc.com). Statistical analysis was performed using R software v4.0.3. P values ​​<0.05 were considered statistically significant. The expression distribution of the RNF122 gene in glioma tissues and normal tissues is shown in Figure 2. Figure 1 As shown, the horizontal axis represents different groups of samples, and the vertical axis represents the distribution of gene expression. The significance of the two groups of samples was tested by Wilcox test. The results showed that the expression of RNF122 in brain glioma tissue was significantly higher than that in normal brain tissue (p<0.0001).

[0027] Example 2 Effect of RNF122 gene expression on the survival rate of patients with brain glioma

[0028] The GEPIA website (http: / / gepia.cancer-pku.cn) was used to analyze the overall survival (OS) between the high and low expression groups of the RNF122 gene in the TCGA-collected glioma patient data set. The parameters were set as follows: group cutoff value, median; confidence interval, 95%; log-rank P value, <0.05. Figure 2The figure shows the effect of RNF122 gene expression on OS of patients with brain glioma. HR represents the risk factor of samples in the high expression group relative to the low expression group. If HR>1, it means that the gene is a risk factor (the higher the expression, the worse the prognosis), and if HR<1, it means that the gene is a protective factor (the higher the expression, the better the prognosis). The results suggest that high expression of RNF122 is a high-risk factor for poor prognosis in patients with brain glioma.

[0029] Example 3 Knockdown of RNF122 gene expression in human glioma U251 cells using siRNA

[0030] The human glioma U251 cell line was purchased from ATCC (Manassas, VA, USA). The cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum at 37°C and 5% CO2 in a humidified environment. 2 × 10 5 U251 cells were seeded in 6-well plates, cultured at 37°C, 5% CO2 for 24 h, and then transfected according to the instructions of Lipofectamine3000.

[0031] The three sequences used to knock down ANKRD18B gene expression are as follows:

[0032] siRNA1#

[0033] The positive strand is 5'-ACAGAAACACCCGUUACACCA-3' (SEQ ID NO.1)

[0034] The antisense strand is 5'-GUGUAACGGGUGUUUCUGUGG-3' (SEQ ID NO. 2)

[0035] siRNA2#

[0036] The positive strand is 5'-UAUAAUUGUAACUUCUUGGCA-3' (SEQ ID NO. 3)

[0037] The antisense strand is 5'-CCAAGAAGUUACAAUUAUAUG-3' (SEQ ID NO. 4)

[0038] siRNA3#

[0039] The positive strand is 5'-AUAUAAUUGUAACUUCUUGGC-3' (SEQ ID NO.5)

[0040] The antisense strand is 5'-CAAGAAGUUACAAUUAUAUGG-3' (SEQ ID NO.6)

[0041] After 48 hours of siRNA transfection, total protein was extracted, and the expression of RNF122 gene in different experimental groups was detected by Western blot technology. Cells were lysed with RIPA lysis buffer containing PMSF, cell proteins were extracted, and protein concentration was determined by BCA method. Proteins were separated by electrophoresis using 10% SDS-PAGE gel. After electrophoresis, the proteins were electrotransferred to PVDF membrane, blocked with 5% skimmed milk powder for 2 hours, and then the membrane was washed 3 times with TBST. The washed membrane was incubated with diluted RNF122 antibody (Invitrogen, 1:800) on a shaker at 4°C overnight, washed 3 times with TBST; then incubated with secondary antibody at room temperature for 1.5 hours, washed 3 times with TBST; finally, developed with ECL. The experimental results are shown in Figure 3 , siRNA1#, siRNA2# and siRNA3# can significantly downregulate the expression of RNF122 protein in glioma cells.

[0042] Example 4 Effect of knocking down the expression of RNF122 gene on the proliferation of glioma cells

[0043] Sustained proliferation signals are an important hallmark of cancer. In order to study the effect of RNF122 knockdown on glioma cell proliferation, we detected cell proliferation by the MTT method. Human glioma U251 cells were cultured in a humid environment of 37°C and 5% CO2 in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum. The cells were divided into a control group and an RNF122 siRNA group. After 48 hours of transfection of glioma cells with siRNA1# described in Example 3, the cells were seeded in a 96-well plate at an initial density of 3000 cells / well. After 48 hours, 5 mg / mL MTT was added to each well, and 20 μL was added to each well. After 4 hours of incubation, we added 150 μL DMSO to dissolve the crystals at an absorbance of 570 nm for 20 minutes, and recorded the experimental data using an enzyme reader. The results are shown in the figure. Figure 4 As shown, the proliferation of cells in the RNF122 siRNA group was significantly lower than that in the control group (P<0.001), indicating that inhibiting the expression of the RNF122 gene can effectively inhibit the proliferation of glioma cells.

[0044] Example 5 Effect of knocking down the expression of RNF122 gene on the cell cycle of glioma cells

[0045] Human glioma U251 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum in a humid environment at 37°C and 5% CO2. The expression of the RNF122 gene was knocked down using siRNA2# described in Example 3. Human glioma U251 cells transfected with siRNA2# for 24 hours were inoculated in a 6-well plate and cultured for 48 hours. The cells were collected by trypsin digestion and fixed with 70% ethanol precooled at 4°C for 24 hours. After fixation, the cells were centrifuged and the fixative was discarded. After washing with PBS, PI dye containing RNAse was added. The cells were incubated at 4°C in the dark for 30 minutes. Finally, the cell cycle was detected by flow cytometry. The results are shown in Figure 5 As shown in the figure, compared with the control group, the cells in the RNF122 siRNA group underwent significant G2 / M phase arrest (P<0.01). These results indicate that the RNF122 gene is a key gene affecting the glioma cell cycle. Silencing the expression of the RNF122 gene will lead to G2 / M phase arrest of glioma cells.

[0046] The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention. For those skilled in the art, it is obvious that the present invention is not limited to the details of the above exemplary embodiments, and the present invention can be implemented in other specific forms without departing from the spirit or basic features of the present invention. Therefore, no matter from which point of view, the embodiments should be regarded as exemplary and non-restrictive. The scope of the present invention is defined by the attached claims rather than the above description, and it is intended to include all changes within the meaning and scope of the equivalent elements of the claims. Although the embodiments of the present invention have been shown and described, it is understood by those of ordinary skill in the art that various changes, modifications, substitutions and variations can be made to these embodiments without departing from the principles and spirit of the present invention, and the scope of the present invention is defined by the attached claims and their equivalents.

Claims

1. An application of a RNF122 inhibitor in the preparation of a glioma drug, wherein the glioma drug is a drug for preventing and treating glioma; the RNF122 inhibitor is RNF122 siRNA; the sense strand of the RNF122 siRNA is the nucleotide sequence shown in SEQ ID NO.1, and the antisense strand of the RNF122 siRNA is the nucleotide sequence shown in SEQ ID NO.

2.

2. An application of an RNF122 inhibitor in the preparation of a glioma drug, wherein the glioma drug is a drug for preventing and treating glioma; the RNF122 inhibitor is RNF122 siRNA; the sense strand of the RNF122 siRNA is the nucleotide sequence shown in SEQ ID NO.3, and the antisense strand of the RNF122 siRNA is the nucleotide sequence shown in SEQ ID NO.

4.

3. A use of an RNF122 inhibitor in the preparation of a glioma drug, wherein the glioma drug is a drug for preventing and treating glioma; the RNF122 inhibitor is RNF122 siRNA; the sense strand of the RNF122 siRNA is the nucleotide sequence shown in SEQ ID NO.5, and the antisense strand of the RNF122 siRNA is the nucleotide sequence shown in SEQ ID NO.6.

Citation Information

Patent Citations

  • Application of RNF122 in preparation of antitumor drugs

    CN114941032A

  • Method for detecting cancer and method for suppressing cancer

    US20070238119A1